Medical treatments with

Mesenchymal Stem Cells (MSCs)

Medical treatments with Mesenchymal Stem Cells (MSCs)

Mesenchymal Stem Cells (MSCs) are one of the most famous stem cell type used in medicine. They have been shown to be effective for a wide range of diseases with a minimal risk profile. At the same time several hundred clinical studies are ongoing to investigate their regenerative abilities in greater detail. From a biological point-of-view, they are progenitor cells of connective tissues. This means that they are important for building and maintaining the healthy status of connective tissues throughout the whole body, and are known as stromal stem cells.

Likewise, they possess the ability to differentiate into a spectrum of other cell types, including chondrocytes (cartilage cells), osteoblasts (bone cells), adipocytes (fat cells), etc. This property classifies them as “multipotent stem cells” (being able to transform into many cell types).

There are several reasons of why they are the leading stem cell type in medical applications and clinical trials on humans:

  • They are relatively easy to harvest and be isolated from:

    • Fat tissue, known as adMSCs (adipose derived MSCs)
    • Bone Marrow, known as bmMSCs (bone marrow MSCs)
    • Umbilical Cord, known as ucMSC (umbilical cord MSCs)
  • MSCs are relatively stable to culture and expand in the laboratory
  • They can go through relatively many division cycles without losing their expression profile, health and division potential
  • Numerous animal, clinical and scientific data collected for various disease models, including neurodegenerative diseases
  • They possess little to no potential to grow into cancer cells
  • As recent research revealed, their stem cell secretome profile is extraordinarily beneficial because it displays a wide range of regenerative and protective abilities to the body.
  • As such, MSCs are our favorite source for making our Stem Cell Secretome therapies.

MSC mesenchymal stem cell flourecent microscope image wideConfocal microscopy image of Mesenchymal Stem Cells (MSCs) with florescence staining

Fat tissue contain MSCs in relatively high concentration. The tissue is processed by enzymatic or microscopical removal of non-cellular parts. This cellular end product is called Stromal Vascular Fraction (SVF). Treatment with SVF can be efficient for treating certain areas and diseases. However, the amount of MSCs it contains is limited. Expansion of MSCs (increasing their cell count in the laboratory) is relatively straightforward. However, this process drastically complicates the clinical application because it impacts the risk profile as well. Due to this fact, this process is highly restricted in all developed countries. The benefit of getting more MSCs is not coupled to obtaining a high cell count, but rather with their viability and their secretion profile.

All this knowledge lead scientists, all over the world, to the next logical step to invent a new generation of Stem Cell treatments: The Stem Cell Secretome. The secretome is designed for superior efficacy, safety and producting the highest concentration of active components responsible for their regenerative powers. Anova IRM has the leading edge in this field; with the most advanced methods, to date, to ensure the most concentrated and effective secretome therapies available for patients, today. For more information on secretome (stem cell-based) treatments, please feel free to contact us.

Why do Mesenchymal Stem Cells have so much healing potential?

Effects of Mesenchymal Stem Cells MSCThe Figure illustrates the effects of MSCs in clinical use. The therapeutic potential of MSCs relies on several unique properties as 1) the capacity to differentiate into various cell lineage, 2) the ability to secrete paracrine factors initiating healing and regeneration in the surrounding cells, 3) the ability to reduce inflammation and regulate immune response, 4) the ability to migrate to the exact site of injury. Figure from [10].

References and Literature - Mesenchymal Stem Cells 'MSCs' (Click for more)

1. Gu W, Zhang F, Xue Q, Ma Z, Lu P, Yu B. Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord. Neuropathology. 2010; 30: 205-217.
2. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res. 2009; 3: 6370
3. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013; 34: 747-754.
4. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2014; 5: 19.
5. Farini, Andrea, et al. "Clinical applications of mesenchymal stem cells in chronic diseases." Stem cells international 2014 (2014).
6. Volarevic, Vladislav, et al. "Concise review: therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis." Stem Cells 32.11 (2014): 2818-2823.
7. Ikebe, Chiho, and Ken Suzuki. "Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols." BioMed research international 2014 (2014).
8. Sharma, Ratti Ram, et al. "Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices." Transfusion 54.5 (2014): 1418-1437.
9. Jo, Chris Hyunchul, et al. "Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof‐of‐concept clinical trial." Stem cells 32.5 (2014): 1254-1266.
10. Squillaro, Tiziana, Gianfranco Peluso, and Umberto Galderisi. "Clinical trials with mesenchymal stem cells: an update." Cell transplantation 25.5 (2016): 829-848.
11. Orozco, Lluis, et al. "Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results." Transplantation 97.11 (2014): e66-e68.
12. Filardo, Giuseppe, et al. "Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics." Knee surgery, sports traumatology, arthroscopy 21.8 (2013): 1717-1729.
13. Jo, Chris Hyunchul, et al. "Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof‐of‐concept clinical trial." Stem cells 32.5 (2014): 1254-1266.
14. Vangsness, C. Thomas, et al. "Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy." J Bone Joint Surg Am 96.2 (2014): 90-98.

Patient Services at Anova IRM Stem Cell Center

Located in the Center of Germany

Less than 20 minutes from Frankfurt Airport

Personalized Therapies for Your Improvement with State-of-the-art Stem Cell products and latest Regenerative Medical Programs

100% Guarantee on Cutting-edge, safe and high quality stem cell products with 20-times increased cell counts

Highest Precision with Latest Radiological Imaging Modalities for Superior Image Guided Procedures

Diagnostic Work-ups with World-Class MRI scans, Advanced Blood Analysis programs and Check-up

Personal Service with Friendly, Dedicated Professional Patient Care Managers

Scientific Collaborations with Renowned Academic Institutions

Scientific Data Acquisition and Publishing

Travel Visa and Concierge Service

Code of Operation, Integrity, Ethical and Legal Framework

Anova IRM works strictly within the German and European legal framework in an ongoing dialog with the German Governement’s regulatory bodies. Use and strategy of any therapy is decided on an individual basis and explicit informed consent with the patient. The Anova clinic operates in full ISO9001 compliance.

Regierungspräsidium Hessen: Darmstadt regional authority
Paul Ehrlich Institute: Federal regulatory authority
European Medicines Agency: Laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use
Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG): Legal framework for trafficing pharmacutical products
Good Manufacturing Practice: Laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use
Advanced Therapy Medicinal Products: Amending Directive 2001/83/EC and Regulation (EC) No 726/2004
Good Clinical Practice: Laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use. Also regulating clinical trials for human use.
ISO9001: Defining fundamentals of quality systems, among others for medical institutes.
Medicinal Product for human use: Amending Directive 2001/83/EC on the Community code
Medical Devices: Council Directive regulating medical devices

Make an Appointment:

Contact us:

Strahlenberger Straße 110
63067 Offenbach am Main

Tel.: +49 (69) 50 50 00 944

Or let us call you back within 24h

Contact us to arrange an appointment

© Anova IRM Stem Cell Center 2017 | All Rights reserved.